Skip to Content

Ocuphire Pharma Inc Ordinary Shares OCUP

Morningstar Rating
$2.01 −0.01 (0.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OCUP is trading at a 55% discount.
Price
$1.96
Fair Value
$2.55
Uncertainty
Extreme
1-Star Price
$24.63
5-Star Price
$4.67
Economic Moat
Gnqd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OCUP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.02
Day Range
$1.992.03
52-Week Range
$1.856.60
Bid/Ask
$2.00 / $2.04
Market Cap
$49.87 Mil
Volume/Avg
124,374 / 206,436

Key Statistics

Price/Earnings (Normalized)
1.54
Price/Sales
2.28
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
14

Comparables

Valuation

Metric
OCUP
VRDN
TARS
Price/Earnings (Normalized)
1.54
Price/Book Value
0.974.016.31
Price/Sales
2.282,495.7261.22
Price/Cash Flow
Price/Earnings
OCUP
VRDN
TARS

Financial Strength

Metric
OCUP
VRDN
TARS
Quick Ratio
13.0717.936.64
Current Ratio
13.3518.266.93
Interest Coverage
−137.76−44.34
Quick Ratio
OCUP
VRDN
TARS

Profitability

Metric
OCUP
VRDN
TARS
Return on Assets (Normalized)
−14.73%−42.76%−50.11%
Return on Equity (Normalized)
−16.08%−82.42%−62.96%
Return on Invested Capital (Normalized)
−16.08%−50.70%−58.53%
Return on Assets
OCUP
VRDN
TARS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFwhffvtfxZdcqg$570.1 Bil
VRTX
Vertex Pharmaceuticals IncJmtppcfgZsghltm$108.0 Bil
REGN
Regeneron Pharmaceuticals IncJxxjvxpHchlcvx$105.6 Bil
MRNA
Moderna IncVkbfxrqvkYfph$40.8 Bil
ARGX
argenx SE ADRBkwzgnpkQpqh$23.5 Bil
BNTX
BioNTech SE ADRTbgjhxqCzdr$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncDlmfbgsbnBrvfqrz$18.8 Bil
BMRN
Biomarin Pharmaceutical IncCrgyxqhlWvcfkg$16.5 Bil
RPRX
Royalty Pharma PLC Class ABpjwjjmpdqPpthvg$13.6 Bil
INCY
Incyte CorpNrklhmmcXwntn$12.8 Bil

Sponsor Center